A Phase 4 interventional study of Insulin and Cyclosporins in Dry Eye and Insulin, sponsored by Barbara Burgos Blasco. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Barbara Burgos Blasco · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.
Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 10th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2022, is one of 5 in phase 4, and was the 28th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:
Barbara Burgos Blasco · Sites in Spain
Ages 18+
Laboratorios Thea, Spain · Sites in Spain
Ages 18+
NOXELIS · Sites in Spain
Ages 18–78
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 8 · Phase 4 5
First in 2009; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 41 interventional studies, 314 across the 3 observational. Of the 37 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 44 have an industry lead sponsor. The 10 most frequent:
Barbara Burgos Blasco is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Barbara Burgos Blasco has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies in Dry Eye Syndromes with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928142Otsuka Pharmaceutical Development & Commercialization, Inc.A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's | 2027-03-13 |
| NCT07715266NOXELISPOST CATARACT SURGERY DRY EYE DISEASE | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Dry Eye Syndromes with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. Topical insulin drops will be compared to the current gold standard treatment, cyclosporin and placebo (artificial tears).
Patients will be recruited in Madrid. Patients with dry eye disease and no topical treatment other than artificial tears will be identified through the Ophthalmology clinic. They will be directly referred to a physician who is participating in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical insulin 1UI/ml 4 times a day
Drug: Insulin
Cyclosporin 0,05% every 12 hours
Drug: Cyclosporins
Artificial tears 4 times a day
Drug: Artificial tears
see arm description
see arm description
see arm description
Change of corneal staining from baseline to 6 months after treatment
Corneal staining will be evaluated on the slit-lamp and on slit-lamp images (masked evaluator)
Time frame: From baseline to 6 months after treatment
Changes in dry eye symptoms from baseline to 6 months after treatment time
Dry eye symptoms will be evaluated using OSDI
Time frame: From baseline to 6 months after treatment
Changes in esthesiometry from baseline to 6 months after treatment time
Esthesiometry will be evaluated using an esthesiometer
Time frame: From baseline to 6 months after treatment
Changes in tear rupture time from baseline to 6 months after treatment time
Tear rupture time will be evaluated using the Keratograph (Oculus)
Time frame: From baseline to 6 months after treatment
Plan to share: No
Ran from Oct 2022 to primary completion in Nov 2025, 36 months.
Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 36 months is above that.
Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin
Barbara Burgos Blasco